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SHORT COMMUNICATION
Prognostic value of continuous variables in breast cancer and head and
neck cancer. Dependence on the cut-off level
A. Courdi, M Hery, P. Chauvel, J. Gioanni, M. Namer & F. Demard
Centre A. Lacassagne, 36 Voie Romaine, 06054 Nice Cedex, France.
An increasing number of clinical, pathological and biological
parameters are being considered in retrospective studies or
prospective clinical trials. One of the leading research aims in
clinical oncology is the definition of prognostic factors
having a predictive power with regard to survival and
disease-free survival of patients. Among the currently used
parameters, some are categorical such as clinical stage or
histological grade, and others are continuous variables that
have many distinct numerical values, such as hormone
receptors or tumour markers. For analysis, continuous
variables are sometimes correlated with other quantitative
parameters, for instance, survival times. More often they
are grouped into 2 or more classes, to be dealt with as
categorical variables. Survival, or any other end-point, of
the so formed groups are then compared by a Chi-square
(x2) test. The way of classification may differ among investi-
gators, often leading to different conclusions about the
influence of this variable on prognosis.
The evaluation of oestrogen receptors (ER) and proges-
terone receptors (PR) in breast cancer is commonly based on
a cut-off value of 10fmolmg-1 protein, which separates
receptor-negative from receptor-positive tumours. However,
not all investigators adopt this value. The labelling index
(LI), which estimates the percent S-phase cells after tritiated
thymidine incorporation, has been recognized as a powerful
predictive factor in breast cancer and in other tumours
(Courdi & Malaise, 1986). Most investigators use the median
LI as a cut-off level to discriminate between slowly prolif-
erating and rapidly proliferating tumours.
We report in this study how the prognostic value of a
continuous variable may be influenced by the cut-off level
chosen, with special reference to ER and PR in breast
cancer, and to LI in breast as well as head and neck cancer.
One hundred and sixty-two node-negative breast cancer
patients treated between 1975 and 1982 and 87 head and
neck cancer patients treated between 1977 and 1982 were
entered in this study. The median length of follow-up for
censored patients was 68 months (range: 23-119) and 56
months (range: 8-114) respectively.
Hormone receptors were assessed in breast cancer by the
dextran charcoal technique (Gioanni et al., 1979). The
median value of ER was 35fmolmg- 1 with a range of 0 and
1,040. Levels higher than 10 fmolmg-1 were observed in 117
cases (72%). PR were measured in 142 cases. The median
value was 45 fmolmg-1 (range: 0-2,350). Levels higher than
10fmolmg-1 were encountered in 111 (78%) cases.
The LI was measured in all patients. It was determined by
a technique previously described (Gioanni et al., 1979). For
breast cancer, the median value was 2.14%, with a range of
0.1 and 9.43. It was 11% in head and neck cancer (range:
2.3-22.45).
Survival was estimated by the Kaplan & Meier method
(1958), and analyzed by the log-rank test. Two groups of
patients were formed according to a certain cut-off value.
Survival of patients having values of less than or equal to
this value was compared to that of patients having values
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greater than it. The x2 with one degree of freedom was
calculated with the corresponding P value. The cut-off level
was then changed and survival of these newly formed groups
was compared and another x2 was computed. This procedure
was applied to ER, PR and LI in breast cancer patients, and
to LI in head and neck cancer patients.
Figure 1 illustrates the dependence of x2 for survival on
the cut-off value of hormone receptors in breast cancer. A
cut-off of 10fmolmg -1 for either ER or PR did not
distinguish between groups having different prognosis since
the points were below the significance level (P=0.05 for
X2=3.84). The highest x2 was observed at an ER cut-off of
20fmolmg-1 (X2 =5.13). For PR, the best discriminant cut-
off was 45fmolmg-1, which was the median value, pointed
out by the right arrow (X2 = 11.04).
The influence of the cut-off value of the LI is shown in
Figure 2. The best discriminant value in breast cancer was
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Figure 1 Chi-square values resulting from log-rank tests coImi-
paring survival of 2 groups of breast cancer patients according to
the cut-off level of ER (0- 0) and PR ( . . ). The
left and right arrows point to the median values of ER and PR
respectively. The horizontal dashed lines give the x2 values
corresponding to 3 levels of statistical significance as read from a
x2 table with one degree of freedom.
LI (%)
Figure 2 Chi-square values resulting from log-rank tests com-
paring survival of 2 groups of patients according to the cut-off
level of LI in breast cancer (0 0) and head and neck
cancer (*.. * ). The left and right arrows point to the
median LI in breast cancer and in head and neck cancer
respectively. The horizontal dashed lines are as in Figure 1.
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close to the median value. However, in head and neck
cancer, the median LI failed to separate between 2 groups
having different prognosis. Higher cut-off values allowed a
distinction between a small group of patients with poor
survival and a bigger number of patients with a significantly
better survival.
These findings raise the question about the way of dealing
with continuous variables if they are intended to influence
prognosis. Since many tests have been applied to the same
population, the reported x2 and the corresponding P value
have to be treated with caution. Indeed, multiple tests carry
the risk of increasing the probability of finding statistically
significant differences which are due to chance. If they are to
be done, the P values should be adjusted accordingly. It
would have been more appropriate in that case to use the x2
table with 2 degrees of freedom (R. Peto, personal communi-
cation). This would raise the horizontal lines of significance
(Figures 1 and 2), for instance by plotting the P=0.05 level
at x2 = 5.99 instead of 3.84. This procedure would have only
changed the significance values, but not the shape of the
curves. However, the aim of this report was not to determine
the exact significance of a certain cut-off level, but rather to
investigate the relative impact of the cut-off value on the
end-point.
Many methods have been described for hormone receptor
assays (Jensen et al., 1971; EORTC breast cancer coopera-
tive group, 1973; Meyer et al., 1978; Wagner, 1978; Wrange
et al., 1978). Moreover, there exists a wide variation in
results among laboratories using the same method (Borjesson
et al., 1987). There is a convention using 10 fmol mg-'
cytosol protein to separate between ER-negative and ER-
positive tumours (McGuire et al., 1975), although many
institutions use lower (Stewart et al., 1982; Hartveit et al.,
1983; Mason et al., 1983; Howat et al., 1985; Bonneterre et
al., 1988) or sometimes higher (Vollenweider-Zerargui et al.,
1986) values. There is greater assay variability for PR
(Jordan et al., 1983) and here again the cut-off values are
variable. The median PR level may be as low as 5 fmolmg-
(Clarke & McGuire, 1983), or as high as 50fmolmg-1
(Bonichon et al., 1988). These great variations cannot be
explained solely by differences in the characteristics of the
patient populations. Values up to 800fmolmg-1 have been
considered as PR-low tumours (Sutton et al., 1987).
Vollenweider-Zerargui et al. (1986) varied systematically the
limits of positivity and negativity to obtain the best
predictive cut-off. Forrest et al. (1980) have also observed
that moving the cut-off value of ER can affect its prognostic
effect. The great variability of institutions in fixing the
threshold of positivity has been recently reviewed (Namer,
1988).
In our study, levels higher than 10fmolmg-I for both ER
and PR are needed to distinguish between good and bad
prognosis patients. In fact, no patient having tumour PR
higher than 45fmolmg-1 died during the follow-up period.
Variations in LI values seem less marked among institu-
tions. Our median LI values in breast cancer as well as in
head and neck cancer are close to those of others (Gentili et
al., 1981; Silvestrini et al., 1984). Yet, in breast cancer, the
median LI seems to be an adequate cut-off to distinguish
between two groups of patients with different outcome. The
fact that most investigators use median LI may explain why
LI is actually a well recognized prognostic factor in breast
cancer (Meyer et al., 1984; Tubiana et al., 1984; Silvestrini et
al., 1986; H6ry et al., 1987). Similar results have been
observed with the percent S-phase fraction as measured by
flow cytometry (Dressler et al., 1988). These investigators
have undertaken cut-off searching studies in their series,
looking for the optimum value (Dressler & McGuire,
personal communication).
The few studies which have addressed the role of the
proportion of S-phase cells on prognosis in head and neck
cancer have reached no clear-cut conclusions (Courdi et al.,
1980; Silvestrini et al., 1984; Muller et al., 1985). This work
suggests that a higher than median cut-off is more optimal
for predicting outcome. In lung cancer, Volm et al. (1985)
have found that a LI cut-off higher than median adverscly
affects survival. In a recent review, we have observed that
the percent S-phase cells is of prognostic significance in 60%
ofthe reported investigations (Courdi & Malaise, 1986). Failure
to detect a link with prognosis may be due to lack of cut-off
searching studies. The reason why the same variable needs to
have different cut-off values according to the tumour type is
unknown and deserves further investigation. The way the LI
influences survival in this study suggests that it is not
necessary to have equal-sized populations on each side of the
cut-off level (by using median values) in order to get out
maximum significance.
Finally, it is hoped that these findings would draw atten-
tion to the fact that arbitrarily taken values to discriminate
between low and high levels of continuous variables may not
be suitable for the classification of patients into low and
high risk groups. We therefore agree with Vollenweider-
Zerargui et al. (1986) in suggesting that each laboratory
should establish adequate cut-off values of these and other
continuous variables in order to achieve the best clinical
correlation.
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